Leslie Popplewell, MD, Oncology, Duarte, CA, City of Hope's Helford Clinical Research Hospital

LeslieLPopplewellMD

Oncology Duarte, CA

City of Hope Medical Group

Dr. Popplewell is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Popplewell's full profile

Already have an account?

Education & Training

  • Memorial Sloan-Kettering Cancer Center
    Memorial Sloan-Kettering Cancer CenterFellowship, Hematology/Oncology, 1995 - 1998
  • Temple University Hospital
    Temple University HospitalResidency, Internal Medicine, 1992 - 1995
  • University of Louisville School of Medicine
    University of Louisville School of MedicineClass of 1992

Certifications & Licensure

  • AZ State Medical License
    AZ State Medical License 2002 - 2017
  • CA State Medical License
    CA State Medical License 1998 - 2023
  • PA State Medical License
    PA State Medical License 1993 - 1995
  • American Board of Internal Medicine Hematology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma  
    Mark P Chao, Sonali M Smith, Ranjana Advani, Ian Flinn, Ravindra Majeti, Nancy L Bartlett, Leslie Popplewell, Justin Kline, Nilanjan Ghosh, Ann LaCasce, The New England Journal of Medicine

Abstracts/Posters

  • CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma
    Leslie L. Popplewell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in...
    Leslie L. Popplewell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Long Term Outcomes of Patients with Aggressive T-Cell Non-Hodgkin Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center
    Leslie L. Popplewell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Phase 1 Study of MDR1 Inhibitor Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Implant-Associated Cancers: A Look Beyond Breast Implant-Associated Anaplastic Large Cell Lymphoma
    Implant-Associated Cancers: A Look Beyond Breast Implant-Associated Anaplastic Large Cell LymphomaSeptember 16th, 2019
  • City of Hope Awarded Lymphoma Specialized Programs of Research Excellence (SPORE) Grant from National Cancer Institute
    City of Hope Awarded Lymphoma Specialized Programs of Research Excellence (SPORE) Grant from National Cancer InstituteFebruary 21st, 2019
  • City of Hope Doctors Present New Research on CAR T Cell Therapy, Bone Marrow Transplants and Other Treatments for Blood Cancers
    City of Hope Doctors Present New Research on CAR T Cell Therapy, Bone Marrow Transplants and Other Treatments for Blood CancersNovember 19th, 2018
  • Join now to see all

Hospital Affiliations